View Cart  

AstraZeneca, Ardelyx to Collaborate on Novel NHE3-Inhibitor Drugs

A A
AstraZeneca (AZ) has agreed to help shepherd Ardelyx’s NHE3-inhibitor program and primary Phase II compound to commercialization, promising to provide the California startup with as much as $272.5 million if new drugs are developed for certain bowel, kidney and renal disorders.

To View This Article:

Login

Subscribe To Drug Industry Daily